Home/Vitara Biomedical/Kim Rodriguez

KR

Kim Rodriguez

Chief Executive Officer (CEO)

Vitara Biomedical

Therapeutic Areas

Neonatology Premature Birth

Vitara Biomedical Pipeline

Drug	Indication	Phase
EXTEND	Support for extremely premature newborns (e.g., 22-28 weeks gestation) to improve survival and reduce severe morbidity	Pre-clinical / Early Feasibility

Leadership Team at Vitara Biomedical

Co-Inventor, Medical Advisor

Co-Inventor, VP Preclinical Research

Neonatology Advisor

Chief Operations Officer

EVP Clinical, Regulatory and Quality

View full Vitara Biomedical profile